

tumors. The presence of metastatic seeding is rare and has been reported as an adverse prognostic factor. We present 2 cases of young children with recurrent metastatic DIA/DIG to describe their presentation, therapeutic management and outcome and to highlight the importance of molecular characterization of these rare tumors to guide adjuvant therapy. **CASES DESCRIPTION:** The first patient developed metastatic recurrence after initial gross total resection (GTR) of a localized DIG. The disseminated relapse was treated with monthly carboplatin and vincristine (CB/VCR). Complete response was achieved after 15 cycles and the patient has remained in continuous complete remission for 5 years. Post hoc molecular analysis of the tumor revealed a BRAF-RDX fusion. The second patient presented with a disseminated intraventricular relapse following an incomplete resection of a DIA associated with a SPECCIL-NTRK2 fusion. The patient received 2 cycles of CB/VCR with minimal response and was then switched to Larotrectinib leading to a very good partial response (VGPR) 3 months into therapy and has remained on treatment since then with significant clinical improvement. **DISCUSSION/ CONCLUSION:** In our 2 cases, metastatic recurrence was responsive to adjuvant therapy leading to complete response with conventional chemotherapy in the first one and to VGPR with NTRK inhibitor in the second patient. Early molecular characterization of these benign tumors is critical in case of incomplete resection or metastatic seeding to widen therapeutic options and maximize chance of cure. Response with NTRK inhibitor appears rapid and significant but the total duration of treatment and sustainability of response after discontinuation remain unknown.

RARE-20. RETROSPECTIVE ANALYSIS OF 9 PINEOBLASTOMA

Ruyi Ai, Juan Li, Mingyao Lai, Linbo Cai; Guangdong Sanjiu Brain Hospital, Guangzhou, Guangdong, China

BACKGROUND: Pineoblastomas (PBs) are rare, supratentorial, primitive neuroectodermal tumors. Little is known with the clinical features and outcomes of PBs. **METHODS:** We retrospectively analyzed consecutive patients with PBs who were treated in Guangdong Sanjiu Brain Hospital between December 2006 to May 2020. **RESULTS:** A total of 9 patients (7 males and 2 females) with PBs were treated in our hospital with a median age of 9 yrs (range: 1-36 yrs) at diagnosis. Total or near-total resection was achieved in 3 patients (33%), partially resection in 4 (44.4%), and biopsy in 2 (22.2%). There were 4 patients have spinal cord metastasis at diagnosis. Five patients received craniospinal irradiation (CSI), with concurrent or adjuvant chemotherapy. The average total dose of CSI was 34.80±2.683Gy, and the average dose to local tumor bed was 56.08±6.41Gy. Two patients younger than 3 years old only received chemotherapy, while 1 patient did not receive any postoperative treatment, and 1 patients was unknown. The median follow-up time is ? months (range: 3-39 months). At the last follow up, 5 patients were died, 3 patients were survived, and 1 was lost to follow-up. The median OS was 31 months (95%CI 1.782-60.281). Disease progression occurred in 5 patients during the follow-up period, and the median PFS was 19 months. **CONCLUSION:** Pineoblastoma is a rare central nervous system malignancy with a tendency for disseminated disease. Comprehensive therapies such as surgical resection, radiation and chemo therapy are effective therapies for PBs.

RARE-21 SOX2 PLAYS AN IMPORTANT ROLE IN CHOROID PLEXUS TUMOR DEVELOPMENT

Lukas Faltings, Tamanna Sarowar, James Virga, Navleen Singh, Brightlyn Kwa, Haotian Zhao; New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York, USA

Choroid plexus (CP) tumors are rare primary brain neoplasms found most commonly in children and are thought to arise from CP epithelial cells. *Sox2* is a transcription factor that not only plays a role in development in the ventricular zone, CP, and roof plate, but also contributes to cancer stemness, tumorigenesis, and drug resistance. Gene expression studies demonstrate aberrant *Sox2* expression in human CP tumors, suggesting a role in tumor development. A subset of CP tumors exhibit abnormal NOTCH pathway activity. Using animal models, we previously show that sustained NOTCH activity leads to CP tumors. Immunofluorescence, RT-qPCR, and RNA scope assays have revealed increased *Sox2* levels in NOTCH-driven CP tumors compared to wild type CP in mice. To investigate the role of *Sox2* in CP tumors, we eliminated *Sox2* expression in NOTCH-driven CP tumors. Loss of *Sox2* almost completely blocked NOTCH-driven CP tumor growth in these mice, supporting a role for *Sox2* in these tumors. Ciliation regulation is one proposed functional pathway for tumorigenesis in CP tumors. Using immunofluorescence assays for cilia (ARL13b) and aquaporin transport protein 1 (AQP1) in combination with super resolution microscopy, we observe a stark contrast between wild type CP epithelial cells which are multiciliated and homogeneously express AQP1, indicative of normal epithelial differentiation, compared to NOTCH-driven CP tumors consisting of mono-ciliated cells with loss of AQP1 expression. In *Sox2*-deficient NOTCH-driven CP tumors, we observe tumor cells remain mono-ciliated and AQP1-negative, indicating that *Sox2* loss does not affect the ciliation machinery. Together this warrants further study into the mechanisms of *Sox2* functions in

CP tumors. By unraveling the role of *Sox2* in CP tumors, we may better understand their origin and biology to ultimately design improved treatment options.

RARE-22 CHARACTERIZING THE LANDSCAPE OF STRUCTURAL VARIANTS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMA

Danny Jomaa^{1,2}, Prasiddha Khadka^{1,2}, Dana Novikov², Alexandra L. Condrat², Jessica W. Tsai^{2,3}, Frank Dubois², Shu Zhang², Kevin Zhou², Rose Gold², Cecilia Sousa², Jayne Vogelzang², Eric Prince^{4,5}, Sophie Lu⁶, Veronika Slivova⁷, Georg W. Otto⁸, Sergi Castellano Hereza⁸, David Ashley⁹, Aaron A. Cohen-Gadol¹⁰, Eric Thompson⁹, Rameen Beroukhi^{2,11}, John Apps^{8,12}, Juan Pedro Martinez-Barbera⁸, Todd Hankinson^{4,5}, Pratiti Bandopadhyay^{2,3}; ¹Harvard Medical School, Boston, MA, USA. ²Dana-Farber Cancer Institute, Boston, MA, USA. ³Boston Children's Hospital, Boston, MA, USA. ⁴Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA. ⁵Morgan Adams Foundation for Pediatric Brain Tumor Research Program, University of Colorado School of Medicine, Aurora, CO, USA. ⁶Milken Institute of Public Health, George Washington University, Washington, DC, USA. ⁷Indiana University Health, Indianapolis, IN, USA. ⁸University College London, London, England, United Kingdom. ⁹Department of Neurosurgery, Duke University, Durham, NC, USA. ¹⁰Department of Neurosurgery, Indiana University, Indianapolis, IN, USA. ¹¹Brigham and Women's Hospital, Boston, MA, USA. ¹²University of Birmingham, Birmingham, England, United Kingdom

INTRODUCTION: Adamantinomatous craniopharyngiomas (ACPs) are rare brain tumors that primarily occur in children and impact long-term morbidity and mortality. The canonical driver mutation for ACP growth occurs in *CTNNB1* and leads to constitutive activation of the Wnt/ β -catenin signaling pathway. In this study, we outline the genomic, transcriptomic, and structural variant (SV) landscape in a cohort of 41 ACP samples. **METHODS:** We performed whole-genome sequencing (WGS) and RNA-sequencing of 41 ACP samples. Matched normal samples were also characterized by WGS. Mutect2 was used to detect single nucleotide variants (SNVs) and indels, and copy number data was generated using the GATK pipeline. SvABA was used to perform SV analysis and to identify significantly recurrent breakpoints and juxtapositions. DESeq2 was used to perform differential gene expression analysis based on clinical and molecular annotation data. **RESULTS:** 29/41 (70%) of the ACP samples harbored missense mutations in exon 3 of *CTNNB1*, all of which have previously been reported in ACP tumors. SV analysis identified a median of 11.5 events per tumor. Overall, 9.7% of events were interchromosomal. Of the remainder, the majority (78.6%) were deletions. No SVs occurred within *CTNNB1*. A positive correlation ($r = 0.533$) was observed between the frequency of SVs and SNVs within samples. Analysis of significantly recurring breakpoints (SRBs) did not identify recurrent breakpoint events. Differential gene expression analysis comparing samples with and without *CTNNB1* variants identified 2,143 differentially expressed genes with q -value < 0.05 . **CONCLUSION:** This study identifies activating mutations in exon 3 of *CTNNB1* in a large cohort of ACP samples. We also integrate SV and transcriptomic data to comprehensively investigate ACP tumor genomes and identify putative novel tumorigenic mechanisms that advance our understanding of ACP biology.

RARE-23. PRESERVATION OF ENDOCRINE FUNCTION AFTER OMMAYA RESERVOIR INSERTION IN CHILDREN WITH CYSTIC CRANIOPHARYNGIOMA

Laura-Nanna Lohkamp, Abhaya V Kulkarni, James Drake, James T Rutka, Jill Hamilton, Ute K Bartels; The Hospital for Sick Children, Toronto, Ontario, Canada

INTRODUCTION: Children with craniopharyngiomas (CP) can be subjected to significant morbidities caused by radical surgery and/or radiation with deleterious long-term consequences. Ommaya reservoir insertion (ORI) into cystic CP represents a minimally invasive procedure allowing immediate decompression and aims to avoid additional injuries. The purpose of this study was to determine the relevance of upfront ORI (+/- intracystic treatment) for preservation of endocrine function. **METHODS:** We performed a retrospective chart review of children with CP treated at the Hospital for Sick Children between 01/01/2000 and 15/01/2020 for review of endocrinological outcome after ORI. Endocrine function was reviewed at the time of initial surgery and throughout the course of follow-up. Event-free survival (EFS) was defined as the time to further surgical resection or irradiation. **RESULTS:** Seventy-nine patients were identified with a median age of 8.3 (range 2.1-18.0) years, 31 were males. Sixty-six patients underwent surgical treatment, including 41 ORI. ORI was performed as upfront treatment in 32 patients; 33 patients underwent gross total or partial resection and 1 patient radiotherapy as first treatment. Fifty-five of 79 patients had sufficient endocrine follow-up data. Endocrine function remained stable after ORI with a mean EFS of 27.64 (± 5.22) months. Surgical resection was associated with worsened endocrine function postoperatively with an EFS of 5.48 (± 1.74) months ($p < 0.001$). **CONCLUSIONS:** Upfront ORI (+/- intracystic treat-